Clinical News

Recent Drug Approvals

November 2014, Vol 4, No 7 - FDA News

FDA Approves First Anti–PD-1: Pembrolizumab Indicated for Advanced Melanoma The FDA approved the first ­­anti–programmed death receptor-1 (PD-1) therapy, pembrolizumab (Keytruda; Merck), for patients with unresectable or metastatic melanoma and disease progression after treatment with other melanoma therapy, such as [ Read More ]

FDA Update

August 2014, Vol 4, No 5 - FDA News

Ofatumumab Approved for Chronic Lymphocytic Leukemia The US Food and Drug Administration approved ofatumumab (Arzerra Injection, GlaxoSmithKline) in combination with chlor­ambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia, for whom fludarabine-based therapy is considered inappropriate. The [ Read More ]